Gentler antibody treatment could tame Slow-Growing lymphoma
NCT ID NCT06442475
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase II trial is testing a low dose of mosunetuzumab, an antibody that helps the immune system attack cancer cells, in 20 people with slow-growing B-cell lymphoma who have not had prior treatment. The goal is to see if this lower dose can shrink tumors while causing fewer side effects. Participants will receive the drug and be monitored for response and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 3A FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mosunetuzumab (a monoclonal antibody)
What this could lead to
If successful, this could offer a gentler treatment option for slow-growing B-cell lymphoma, potentially controlling the disease with fewer side effects.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug can cause serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.